Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: A randomized controlled trial

M. Busacca, E. Somigliana, S. Bianchi, S. De Marinis, C. Calia, M. Candiani, M. Vignali

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Background: In order to decrease endometriosis recurrence after surgical therapy, it has been proposed to use a post-surgical oestrogen-lowering medical treatment. Results from previous trials on this topic are contradictory. Methods: A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an expectant management (n = 45). All patients were followed up every 6 months for evaluation of pain symptoms, fertility and objective disease recurrence. Results: During the follow-up, which ranged from 6-36 months, five (33%) of the 15 women who wanted children and who were allocated the GnRH analogue and six (40%) of the 15 given no treatment became pregnant (not significant). Moderate/severe pelvic pain recurred during the follow-up in 10 (23%) of the women allocated the GnRH analogue and 11 (24%) of those allocated no treatment; the cumulative pain recurrence rates at 18 months were 23 and 29% respectively (not significant). Four women (9%) treated with GnRH analogue and four women (9%) who received no treatment had objective disease recurrence as demonstrated by gynaecological examination and/or pelvic ultrasonography. Conclusions: This study does not support the routine post-operative use of a 3 month course of GnRH analogue in women with symptomatic endometriosis stage III-IV.

Original languageEnglish
Pages (from-to)2399-2402
Number of pages4
JournalHuman Reproduction
Volume16
Issue number11
Publication statusPublished - 2001

Fingerprint

Endometriosis
Gonadotropin-Releasing Hormone
Randomized Controlled Trials
Recurrence
Leuprolide
Therapeutics
Pain
Gynecological Examination
Pelvic Pain
Symptom Assessment
Laparoscopy
Fertility
Conservative Treatment
Ultrasonography
Estrogens
Injections

Keywords

  • Endometriosis
  • Gonadotrophin-releasing hormone analogue
  • Laparoscopy

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV : A randomized controlled trial. / Busacca, M.; Somigliana, E.; Bianchi, S.; De Marinis, S.; Calia, C.; Candiani, M.; Vignali, M.

In: Human Reproduction, Vol. 16, No. 11, 2001, p. 2399-2402.

Research output: Contribution to journalArticle

@article{886524b77e8c4b53b0ee4d232e6b456e,
title = "Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: A randomized controlled trial",
abstract = "Background: In order to decrease endometriosis recurrence after surgical therapy, it has been proposed to use a post-surgical oestrogen-lowering medical treatment. Results from previous trials on this topic are contradictory. Methods: A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an expectant management (n = 45). All patients were followed up every 6 months for evaluation of pain symptoms, fertility and objective disease recurrence. Results: During the follow-up, which ranged from 6-36 months, five (33{\%}) of the 15 women who wanted children and who were allocated the GnRH analogue and six (40{\%}) of the 15 given no treatment became pregnant (not significant). Moderate/severe pelvic pain recurred during the follow-up in 10 (23{\%}) of the women allocated the GnRH analogue and 11 (24{\%}) of those allocated no treatment; the cumulative pain recurrence rates at 18 months were 23 and 29{\%} respectively (not significant). Four women (9{\%}) treated with GnRH analogue and four women (9{\%}) who received no treatment had objective disease recurrence as demonstrated by gynaecological examination and/or pelvic ultrasonography. Conclusions: This study does not support the routine post-operative use of a 3 month course of GnRH analogue in women with symptomatic endometriosis stage III-IV.",
keywords = "Endometriosis, Gonadotrophin-releasing hormone analogue, Laparoscopy",
author = "M. Busacca and E. Somigliana and S. Bianchi and {De Marinis}, S. and C. Calia and M. Candiani and M. Vignali",
year = "2001",
language = "English",
volume = "16",
pages = "2399--2402",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV

T2 - A randomized controlled trial

AU - Busacca, M.

AU - Somigliana, E.

AU - Bianchi, S.

AU - De Marinis, S.

AU - Calia, C.

AU - Candiani, M.

AU - Vignali, M.

PY - 2001

Y1 - 2001

N2 - Background: In order to decrease endometriosis recurrence after surgical therapy, it has been proposed to use a post-surgical oestrogen-lowering medical treatment. Results from previous trials on this topic are contradictory. Methods: A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an expectant management (n = 45). All patients were followed up every 6 months for evaluation of pain symptoms, fertility and objective disease recurrence. Results: During the follow-up, which ranged from 6-36 months, five (33%) of the 15 women who wanted children and who were allocated the GnRH analogue and six (40%) of the 15 given no treatment became pregnant (not significant). Moderate/severe pelvic pain recurred during the follow-up in 10 (23%) of the women allocated the GnRH analogue and 11 (24%) of those allocated no treatment; the cumulative pain recurrence rates at 18 months were 23 and 29% respectively (not significant). Four women (9%) treated with GnRH analogue and four women (9%) who received no treatment had objective disease recurrence as demonstrated by gynaecological examination and/or pelvic ultrasonography. Conclusions: This study does not support the routine post-operative use of a 3 month course of GnRH analogue in women with symptomatic endometriosis stage III-IV.

AB - Background: In order to decrease endometriosis recurrence after surgical therapy, it has been proposed to use a post-surgical oestrogen-lowering medical treatment. Results from previous trials on this topic are contradictory. Methods: A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an expectant management (n = 45). All patients were followed up every 6 months for evaluation of pain symptoms, fertility and objective disease recurrence. Results: During the follow-up, which ranged from 6-36 months, five (33%) of the 15 women who wanted children and who were allocated the GnRH analogue and six (40%) of the 15 given no treatment became pregnant (not significant). Moderate/severe pelvic pain recurred during the follow-up in 10 (23%) of the women allocated the GnRH analogue and 11 (24%) of those allocated no treatment; the cumulative pain recurrence rates at 18 months were 23 and 29% respectively (not significant). Four women (9%) treated with GnRH analogue and four women (9%) who received no treatment had objective disease recurrence as demonstrated by gynaecological examination and/or pelvic ultrasonography. Conclusions: This study does not support the routine post-operative use of a 3 month course of GnRH analogue in women with symptomatic endometriosis stage III-IV.

KW - Endometriosis

KW - Gonadotrophin-releasing hormone analogue

KW - Laparoscopy

UR - http://www.scopus.com/inward/record.url?scp=0035148999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035148999&partnerID=8YFLogxK

M3 - Article

C2 - 11679528

AN - SCOPUS:0035148999

VL - 16

SP - 2399

EP - 2402

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 11

ER -